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For clinical researchers, it is the best of times and the
worst of times. The best of times because recent biomedical
discoveries hold so much potential promise for our patients.
The worst of times because the current regulatory climate
surrounding clinical research has become fraught with fear
and anxiety for patients, researchers, and the general public
as a result of inconsistent institutional oversight of research
involving human subjects.
In this light, all clinical researchers engaged in hemato-
poietic stem cell transplantation (HSCT) trials will be inter-
ested in the report by Martin et al. found in this issue of Biology
of Blood and Marrow Transplantation [1]. The article summarizes
recommendations for adverse event (AE) reporting in clinical
trials involving HSCT. The authors ﬁrst compare relevant
portions of current federal regulations, guidelines from the
International Conference on Harmonization (ICH), and Stan-
dards from the National Cancer Institute (NCI) for AE report-
ing. These regulations, guidelines, and standards all differ from
each other in important details, contributing to the confusion of
who is supposed to report what when. The federal regulations
are, of course, the law of the land, and they provide speciﬁc def-
initions critical to AE reporting, such as “serious” and “unex-
pected,” which trigger the need for expedited reports. ICH
guidelines require a high level of detail in all AE reports regard-
less of severity or relationship to study drug, creating burden-
some reports in HSCT trials when AEs are already numerous.
The NCI standards, with Common Toxicity Criteria (CTC)
scales that are partially customized for HSCT, provide stan-
dardized criteria that should improve the consistency of AE data
across different institutions and help facilitate multicenter trials. 
The authors propose nine recommendations to improve
AE reporting in HSCT clinical trials. The heart of the pro-
posals is the ﬁfth recommendation, that the level of detail in
AE reports should be calibrated both to the severity of the
AE and its perceived relationship to study drug (italics
added). The three recommended levels of reporting would
focus attention on AEs that are more severe or that are
more likely to be related to the study drug. Long, repetitive
lists of recurrent AEs that are of low severity or that have
little relationship to the investigational agent will be signiﬁ-
cantly reduced. Currently such lists account for a large
fraction of AE reports and the change would encourage
reporting in real time as opposed to tedious and frequently
inaccurate retrospective chart reviews. A second recommen-
dation flows directly from this one, to calibrate the time
window of AE monitoring by the severity/perceived rela-
tionship to study drug. Expedited reports would thus be
fewer but more meaningful.
As a whole the recommendations are eminently sensible and
reﬂect a thoughtful consensus of seasoned and distinguished
clinical investigators who have struggled long and hard with
these issues. A couple of proposals will require further ﬁne-tun-
ing (eg, which asAEs should be exempt from mandatory report-
ing). But there can be no doubt that the current practice of “all-
inclusive” reporting of AEs generates such a low signal-to-noise
ratio that it sometimes precludes the emergence of an accurate
safety proﬁle of a new drug used during HSCT. The cost and
time to bring new products and devices from discovery to clini-
cal use has grown considerably over the years. As noted in a
recent editorial in a lay publication [2], eight of the top 15 phar-
maceutical companies did not receive any new FDA approvals
last year despite spending $30 billion on research and develop-
ment, a 15-fold increase compared to 1980. The pressures to
return a proﬁt most certainly mean that some drugs or devices
potentially useful to only small numbers of patients will never be
developed. Costly regulatory guidelines that are entirely appro-
priate to protect large numbers of patients with chronic or non-
severe illnesses may not best suit situations with small numbers
of patients with life-threatening illnesses. Continuous attention
to reﬁning regulatory oversight of “orphan” drugs and devices
for HSCT patients, as is manifest in the report by Martin et al.,
is needed to balance the need for patient protection without hin-
dering innovation to improve transplantation outcomes. 
The reporting burden engendered by the overzealous
interpretation of regulations may soon convince some investi-
gators in the clinical trenches simply not to participate in oth-
erwise potentially important research. That would be a signiﬁ-
cant loss for all of us, particularly for our patients who deserve
medicines that have been rigorously tested in clinical trials.
From this perspective, the authors have performed an impor-
tant service for the BMT HSCT community by producing this
timely and carefully considered report. It serves as an excellent
starting point in which investigators, sponsors, and regulatory
agencies should be able to ﬁnd much common ground.
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